JP2003513062A - 塩酸セルトラリンの多形形態 - Google Patents

塩酸セルトラリンの多形形態

Info

Publication number
JP2003513062A
JP2003513062A JP2001534755A JP2001534755A JP2003513062A JP 2003513062 A JP2003513062 A JP 2003513062A JP 2001534755 A JP2001534755 A JP 2001534755A JP 2001534755 A JP2001534755 A JP 2001534755A JP 2003513062 A JP2003513062 A JP 2003513062A
Authority
JP
Japan
Prior art keywords
sertraline hydrochloride
sertraline
hydrochloride
csc1
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001534755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003513062A5 (cg-RX-API-DMAC7.html
Inventor
デル スハーフ,パウル アドリアーン ヴァン
シュヴァルツェンバッハ,フランツ
キルナー,ハンス−イェルク
シェラギエヴィッツ,マルティン
マルコルリ,クラウディア
ブルクハルト,アンドレアス
ペーター,レギーネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Schweiz AG
Original Assignee
Ciba Spezialitaetenchemie Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8243113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2003513062(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Spezialitaetenchemie Holding AG filed Critical Ciba Spezialitaetenchemie Holding AG
Publication of JP2003513062A publication Critical patent/JP2003513062A/ja
Publication of JP2003513062A5 publication Critical patent/JP2003513062A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001534755A 1999-10-29 2000-10-23 塩酸セルトラリンの多形形態 Withdrawn JP2003513062A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99810981.3 1999-10-29
EP99810981 1999-10-29
PCT/EP2000/010416 WO2001032601A1 (en) 1999-10-29 2000-10-23 Polymorphic forms of sertraline hydrochloride

Publications (2)

Publication Number Publication Date
JP2003513062A true JP2003513062A (ja) 2003-04-08
JP2003513062A5 JP2003513062A5 (cg-RX-API-DMAC7.html) 2007-12-06

Family

ID=8243113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001534755A Withdrawn JP2003513062A (ja) 1999-10-29 2000-10-23 塩酸セルトラリンの多形形態

Country Status (17)

Country Link
US (2) US6872853B1 (cg-RX-API-DMAC7.html)
EP (1) EP1224160B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003513062A (cg-RX-API-DMAC7.html)
CN (1) CN1384816A (cg-RX-API-DMAC7.html)
AR (1) AR026293A1 (cg-RX-API-DMAC7.html)
AT (1) ATE409684T1 (cg-RX-API-DMAC7.html)
AU (1) AU1386301A (cg-RX-API-DMAC7.html)
CA (1) CA2387135A1 (cg-RX-API-DMAC7.html)
DE (1) DE60040406D1 (cg-RX-API-DMAC7.html)
HU (1) HUP0203559A3 (cg-RX-API-DMAC7.html)
IL (2) IL149050A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA02004255A (cg-RX-API-DMAC7.html)
MY (1) MY141509A (cg-RX-API-DMAC7.html)
TR (1) TR200201146T2 (cg-RX-API-DMAC7.html)
TW (1) TWI260315B (cg-RX-API-DMAC7.html)
WO (1) WO2001032601A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200203254B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1630156A1 (en) * 1998-11-27 2006-03-01 Teva Pharmaceutical Industries Ltd Sertraline hydrochloride polymorphs
IL143311A0 (en) * 1998-11-27 2002-04-21 Teva Pharma Sertraline hydrochloride polymorphs
US6500987B1 (en) * 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
EP1774965A3 (en) * 1999-12-21 2007-10-10 Teva Pharmaceutical Industries Ltd Novel sertraline hydrochloride polymorph, processes for preparing them, compositions containing them and methods of using them
YU47902A (sh) * 1999-12-21 2005-11-28 Teva Pharmaceutical Industries Ltd. Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu
IN192343B (cg-RX-API-DMAC7.html) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
US7067700B2 (en) 2001-05-31 2006-06-27 Fermion Oy Process for preparing sertraline hydrochloride polymorphic form II
EP1499581A1 (en) 2002-04-29 2005-01-26 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
CN102215522A (zh) * 2002-06-27 2011-10-12 美商内数位科技公司 宽频码分多址第一无线网络控制器
JP2007502329A (ja) 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
CA2544684A1 (en) 2003-11-04 2005-05-26 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
EP1711493A2 (en) * 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
EP1893559A2 (en) * 2005-06-09 2008-03-05 Teva Pharmaceutical Industries Ltd Process for preparation of sertraline hydrochloride form i
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
CA2594198A1 (en) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. A novel process for the preparation of sertraline hydrochloride form ii
US9993793B2 (en) 2010-04-28 2018-06-12 The Procter & Gamble Company Delivery particles
US9186642B2 (en) 2010-04-28 2015-11-17 The Procter & Gamble Company Delivery particle
US8980292B2 (en) 2011-04-07 2015-03-17 The Procter & Gamble Company Conditioner compositions with increased deposition of polyacrylate microcapsules
WO2012138710A2 (en) 2011-04-07 2012-10-11 The Procter & Gamble Company Personal cleansing compositions with increased deposition of polyacrylate microcapsules
US8927026B2 (en) 2011-04-07 2015-01-06 The Procter & Gamble Company Shampoo compositions with increased deposition of polyacrylate microcapsules
CN105061217A (zh) * 2015-06-30 2015-11-18 徐静 枸橼酸舍曲林的2种晶型及其制备方法
EP4229164A1 (en) 2020-10-16 2023-08-23 The Procter & Gamble Company Consumer product compositions with at least two encapsulate populations
JP7719177B2 (ja) 2020-10-16 2025-08-05 ザ プロクター アンド ギャンブル カンパニー 封入体の集団を含む消費者製品組成物
US12486478B2 (en) 2020-10-16 2025-12-02 The Procter & Gamble Company Consumer products comprising delivery particles with high core:wall ratios
CN112552188B (zh) * 2020-12-17 2023-07-28 山西仟源医药集团股份有限公司 盐酸舍曲林晶型i的制备方法
CN113588626B (zh) * 2021-08-24 2024-05-24 上海师范大学 一种苯丙氨酸对映体的拉曼光谱检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US5082970A (en) 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
CA2323629A1 (en) 1998-03-18 1999-09-23 Ciba Specialty Chemicals Holding Inc. Process for the cis-selective catalytic hydrogenation of cyclohexylidenamines
JP2000026378A (ja) 1998-07-03 2000-01-25 Sumika Fine Chemicals Co Ltd 塩酸セルトラリンの製法
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
IL143311A0 (en) * 1998-11-27 2002-04-21 Teva Pharma Sertraline hydrochloride polymorphs
US6495721B1 (en) 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
YU47902A (sh) 1999-12-21 2005-11-28 Teva Pharmaceutical Industries Ltd. Novi polimorfi sertralin hidrohlorida, postupci za njihovo dobijanje, preparati koji ih sadrže i postupci za njihovu upotrebu

Also Published As

Publication number Publication date
US6939992B2 (en) 2005-09-06
DE60040406D1 (de) 2008-11-13
ATE409684T1 (de) 2008-10-15
AU1386301A (en) 2001-05-14
EP1224160A1 (en) 2002-07-24
TR200201146T2 (tr) 2004-12-21
US20040132828A1 (en) 2004-07-08
MY141509A (en) 2010-05-14
HUP0203559A3 (en) 2008-01-28
HUP0203559A2 (hu) 2003-03-28
ZA200203254B (en) 2003-07-22
IL149050A (en) 2007-03-08
MXPA02004255A (es) 2002-10-17
TWI260315B (en) 2006-08-21
CA2387135A1 (en) 2001-05-10
AR026293A1 (es) 2003-02-05
WO2001032601A1 (en) 2001-05-10
IL149050A0 (en) 2002-11-10
CN1384816A (zh) 2002-12-11
EP1224160B1 (en) 2008-10-01
US6872853B1 (en) 2005-03-29

Similar Documents

Publication Publication Date Title
US6872853B1 (en) Polymorphic forms of sertraline hydrochloride
JP2005503386A5 (cg-RX-API-DMAC7.html)
JPWO1999065885A1 (ja) 2−(3−シアノ−4−イソブチルオキシフェニル)−4−メチル−5−チアゾールカルボン酸の結晶多形体およびその製造方法
JPH0249797A (ja) エリスロマイシンaオキシム及びその塩の製造方法
JP2001508077A (ja) 2−アミノ−4−(4−フルオルベンジルアミノ)−1−エトキシカルボニル−アミノベンゼンの新規変態ならびにその製造法
JP2002519422A (ja) パロキセチンメタンスルホネート
JP2005509025A5 (cg-RX-API-DMAC7.html)
EP0579681B1 (en) Crystalline tiagabine hydrochloride monohydrate, its preparation and use
JP4180368B2 (ja) 塩酸ベンラファキシンの結晶形
JP2019523273A (ja) ベリノスタットの多形形態、およびその調製のためのプロセス
US20060079706A1 (en) Bicalutamide polymorphs
JP2003503477A (ja) アムロジピンベンゼンスルホン酸塩の製造方法
NZ523528A (en) Novel form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro-2-naphthyl}-4-morpholinobenzamide
JP4538842B2 (ja) 新規ナテグリニド結晶
JP2002531427A (ja) セルトラリン塩酸塩多形体
US7442838B2 (en) Polymorphic forms of sertraline hydrochloride
JP2002505254A (ja) パロキセチン塩
JP2002526498A (ja) ナフチリジンカルボン酸誘導体(メタンスルホネート・セスキ水和物)の製法
JPH08511008A (ja) 複素環式化学
EP2155698A1 (en) Novel thermodynamically stable polymorphic form-l of letrozole
JP2001502663A (ja) 置換バリンアミド誘導体の製造方法
JPH10506653A (ja) ヨウ素化造影剤の製造方法
US6861525B2 (en) Process for the preparation imidazo[1,2-A]pyridine-3-acetamides
JP2002532510A (ja) クラリスロマイシンの製造に於けるマクロライド中間体
JP2003502422A (ja) パロキセチンおよび構造上関連する化合物の製法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071018

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080723